Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2 — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2 — Stella

Recruiting

Back to Long COVID trials

Not a traditional drug trial — this study doesn't follow the standard phase structure.

Trial locations(2 sites)

United States

Clinical and Translational Research Unit, Palo Alto, California

Stanford Health, Palo Alto, California

Key details

Sponsor

Stanford University

Enrollment target

~55 participants

Started

June 2023

Primary completion

May 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 80 Years

Last updated December 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov